

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	NA

*FHK- Florida Healthy Kids

Non-Preferred High Potency Topical Corticosteroids

Override(s)	Approval Duration
Prior Authorization	1 year

Medications	Comment
Amcinonide 0.1% ointment/lotion	Preferred
Betamethasone dipropionate 0.05% lotion	Preferred
Betamethasone dipropionate augmented 0.05% cream	Preferred
Betamethasone valerate 0.1% ointment	Preferred
Diflorasone 0.05% cream	Preferred
Fluocinonide-E 0.05% cream	Preferred
Triamcinolone 0.5% cream/ointment	Preferred
Amcinonide 0.1% cream	Non-Preferred
Apexicon E 0.05% cream	Non-Preferred
Betamethasone dipropionate 0.05% cream/ointment	Non-Preferred
Betamethasone dipropionate augmented 0.05% lotion/gel	Non-Preferred
Desoximetasone 0.05% gel, 0.25% cream/ointment/spray	Non-Preferred
Diprolene 0.05% lotion	Non-Preferred
Diprolene AF 0.05% cream	Non-Preferred
Fluocinonide 0.5% cream/gel/ointment/solution, 0.1% cream	Non-Preferred
Halog 0.1% cream/ointment	Non-Preferred
Psorcon 0.05% cream	Non-Preferred
Sernivo 0.05% spray	Non-Preferred
Topicort 0.05% gel, 0.25% cream/ointment/spray	Non-Preferred
Triderm 0.5% cream	Non-Preferred
Vanos 0.1% cream	Non-Preferred

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	NA

*FHK- Florida Healthy Kids

APPROVAL CRITERIA

Requests for a non-preferred high potency topical corticosteroid may be approved when the following criteria are met:

- I. Individual has had a trial and inadequate response or intolerance to two preferred high potency topical corticosteroids; **OR**
- II. The preferred agents are not FDA-approved for the prescribed indication; **OR**
- III. The preferred agents are not acceptable due to concomitant clinical situations, such as but not limited to the following:
 - A. Individual requires an alternate dosage form.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2016. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>.

DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2016; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.